RiverGlades Family Offices’s Bristol-Myers Squibb BMY Stock Holding History

RiverGlades Family Offices’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,650	Closed	-$352K	–	84
2021 Q4	$352K	Hold	5,650	–	–	0.26%	62
2021 Q3	$334K	Hold	5,650	–	–	0.26%	58
2021 Q2	$378K	Hold	5,650	–	–	0.29%	54
2021 Q1	$357K	Sell	5,650 -150	-3%	-$9.33K	0.29%	54
2020 Q4	$360K	Sell	5,800 -1,200	-17%	-$73.8K	0.31%	52
2020 Q3	$422K	Hold	7,000	–	–	0.4%	41
2020 Q2	$412K	Sell	7,000 -300	-4%	-$17.9K	0.42%	44
2020 Q1	$407K	Hold	7,300	–	–	0.43%	39
2019 Q4	$469K	Sell	7,300 -1,000	-12%	-$57.3K	0.4%	42
2019 Q3	$421K	Hold	8,300	–	–	0.38%	43
2019 Q2	$376K	Buy	8,300 +1,100	+15%	+$51.2K	0.34%	48
2019 Q1	$344K	Buy	+7,200	New	+$359K	0.31%	50
2018 Q4	–	Sell	-6,200	Closed	-$385K	–	43
2018 Q3	$385K	Sell	6,200 -60	-1%	-$3.56K	0.33%	48
2018 Q2	$346K	Sell	6,260 -4,740	-43%	-$256K	0.3%	51
2018 Q1	$696K	Buy	11,000 +2,115	+24%	+$136K	0.55%	34
2017 Q4	$544K	Buy	+8,885	New	+$556K	0.45%	37

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

RiverGlades Family Offices's BMY Position: Q1 2022 in Review

RiverGlades Family Offices sold out of Bristol-Myers Squibb (BMY) in Q1 2022, closing a stake of 5,650 shares — an estimated $352K sold.

RiverGlades Family Offices first reported a position in BMY in Q4 2017 and held it in 16 quarters. The position peaked at $696K in Q1 2018. 2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

RiverGlades Family Offices reported no remaining Bristol-Myers Squibb position as of Q1 2022 after selling out during the quarter.
RiverGlades Family Offices sold 5,650 Bristol-Myers Squibb shares in Q1 2022, an estimated $352K.
RiverGlades Family Offices first reported a position in Bristol-Myers Squibb in Q4 2017 and held it in 16 quarters.
RiverGlades Family Offices's Bristol-Myers Squibb position peaked at $696K in Q1 2018.
2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on RiverGlades Family Offices's 13F filing for Q1 2022, filed 11 May 2022.